Health & Medical News

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial - The Lancet thumbnail

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet

SummaryBackgroundRight here's the first randomised managed trial for review of the immunogenicity and safety of a candidate non-replicating adenovirus form-5 (Ad5)-vectored COVID-19 vaccine, aiming to resolve an acceptable dose of the candidate vaccine for an efficacy see.ProgramsThis randomised, double-blind, placebo-managed,…

yeoys logo